BackSerina Therapeutics Overview

Serina Therapeutics Total Revenue

Track Serina Therapeutics's total revenue ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Jun 2026

Annual Revenue (TTM)

N/A

Trailing 12 months ending Jun 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Serina Therapeutics (SER) FAQ

Serina Therapeutics (SER) currently reports a total revenue of $0 as of June 2026. That compares with $130K in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Serina Therapeutics's total revenue history and peer comparisons.

Serina Therapeutics's total revenue decreased from $130K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Serina Therapeutics's total revenue of $0 is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Serina Therapeutics reported $0 in total revenue as of June 2026. That compares with $130K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Serina Therapeutics, and consider following SER for alerts when major investors trade the stock.